HIV drug dosing study aims to protect moms and babies
NCT ID NCT05630638
First seen Feb 23, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study looks at how well the HIV drug doravirine works in pregnant women. It involves 76 women who start HIV treatment in their second trimester. The goal is to find the right dose to keep the mother healthy and reduce risks to the baby.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Desmond Tutu Health Foundation
RECRUITINGCape Town, South Africa
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.